Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178922 | 0.85 | MAPK14 (0.66) | MAPK14NPC1ALDH1A1HPGDMCHR1 | |
| SCHEMBL2176386 | 0.84 | KDM4E (0.45) | MAPK14KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL2175647 | 0.84 | MAPK14 (0.51) | MAPK14KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL2175574 | 0.83 | MAPK14 (0.41) | MAPK14KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL2175391 | 0.80 | MAPK14 (0.46) | MAPK14KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL2177276 | 0.80 | MAPK14 (0.52) | MAPK14MCHR1 | |
| SCHEMBL2180062 | 0.79 | KDM4E (0.40) | MAPK14KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL2176365 | 0.78 | MCHR1 (0.39) | MAPK14KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL2174324 | 0.78 | MAPK14 (0.41) | MAPK14KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL2177726 | 0.76 | MCHR1 (0.41) | MAPK14KDM4ENPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101282930-B | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS INC | 2012-10-24 | — | — | CN | claimed |
| CN-101282930-A | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS INC (KR) | 2008-10-08 | — | — | CN | claimed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | claimed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | claimed |
| CN-101282930-B | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS INC | 2012-10-24 | — | — | CN | disclosed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| CN-101282930-A | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS INC (KR) | 2008-10-08 | — | — | CN | disclosed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | MAPK14 1791/4885SNRNP200 1541/4885KDM4E 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.